Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity. The company builds upon the $100+ million invested in Klotho related academic research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents pending on modified, recombinant Klotho proteins that can be readily manufactured using standard cell culture technology.

KTI is minimizing the standard risks of an early stage biotech by de-risking each component of the development process. Its capital efficient structure will reduce the cost and time of getting to human trials. KTI is well positioned to enter human trials within 12-15 months focused on its first indication: to slow the progression of kidney failure, which affects up to 40 million patients in the US per year, with over 600,000 currently on dialysis. Kidney disease represents a multi-billion dollar market opportunity in the U.S. alone.